Elekta

iCAD Reports Financial Results for Third Quarter Ended September 30, 2023

Retrieved on: 
Monday, November 13, 2023
Cloud, Sale, Woman, Pressure, Annual, Research, ICAD, Patient, Science, Artificial intelligence, ARR, Cancer, Partnership, Risk, Growth, AI, Renting, Music, Video game, Elekta

NASHUA, N.H., Nov. 13, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three and nine months ended September 30, 2023.

Key Points: 
  • NASHUA, N.H., Nov. 13, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three and nine months ended September 30, 2023.
  • Company re-introduces Annual Recurring Revenue (ARR) metrics to highlight progress of subscription sales and growing recurring revenue model.
  • Subscription ARR (S-ARR) represents the annualized value of active subscription or term licenses at the end of a reporting period.
  • Three Months Ended September 30, 2023 Financial Results
    Total revenue for our Detection business for the third quarter of 2023 was $4.1 million, a decrease of $0.3 million, or 7%, as compared to the third quarter of 2022.

Rapid Growth at Attune Medical Spurs Strategic Hires and Expansion

Retrieved on: 
Thursday, December 14, 2023
Science, Cardiology, Biotechnology, Research, Surgery, General Health, Health, Medical Devices, Associate, Safety, De novo, Quality, Regulatory affairs, Esophagus, University, Digital, MBE, Clinical trial, Clinical research, Fluoroscopy, Multimedia, Patient, Medicine, FDA, Electrophysiology, Marketing, Atrial fibrillation, FHRS, Elekta, NIH, MPH, RAC, Growth, Hospital, Teva Pharmaceuticals, Temperature, CBA, Video game, Medical device, Pharmaceutical industry, MD

Attune Medical, a pioneer in utilizing the esophageal space to proactively manage patient temperature and to reduce the likelihood of esophageal injury during cardiac ablation procedures, announces significant growth with three key additions and expansion of commercial operations.

Key Points: 
  • Attune Medical, a pioneer in utilizing the esophageal space to proactively manage patient temperature and to reduce the likelihood of esophageal injury during cardiac ablation procedures, announces significant growth with three key additions and expansion of commercial operations.
  • (Graphic: Business Wire)
    Melinda Smith, MS, RAC, CBA, joins Attune Medical as VP of Regulatory Affairs leading our global regulatory strategy.
  • In her role with Attune Medical, she will expand efforts in clinical research and study start-up while managing high-profile NIH funded clinical trial efforts.
  • In addition, the company is actively expanding its commercial and clinical teams to accommodate the rapid growth it is experiencing.

RPS Oncology partners with Elekta to elevate cancer care across the Americas

Retrieved on: 
Wednesday, December 6, 2023
Cancer, Patient, Partnership, Organization, Elekta, Physics, Health, Medical imaging, Nursing

Recognizing RPS Oncology's expertise and commitment to excellence, Elekta has selected the company as a key partner in its Elekta Care 360 value-added services portfolio.

Key Points: 
  • Recognizing RPS Oncology's expertise and commitment to excellence, Elekta has selected the company as a key partner in its Elekta Care 360 value-added services portfolio.
  • "Being chosen as an Elekta Care 360 partner is a testament to our dedication to outstanding patient care.
  • Ferhan Bulca, Vice President and Head of Value-Added Services at Elekta stated, "RPS Oncology is a crucial addition to our network, reinforcing our commitment to elevate cancer care standards across the Americas.
  • As a valued partner in the Elekta Care 360 program, RPS Oncology will collaborate closely with Elekta to integrate its specialized services into Elekta's comprehensive cancer care solutions.

Global Leader Advancing Cancer Treatment, Dr. Christel Smith, Joins Fuse Oncology as Chief Technology Officer

Retrieved on: 
Monday, November 20, 2023
GPU, Medicine, Research, Physics, Breast cancer, Patient, Radiation therapy, Product management, Flash, Varian Medical Systems, Elekta, University, Software, Cancer, UCSD, Management, Medical imaging, Fuse, Varian

BOONE, N.C., Nov. 20, 2023 /PRNewswire/ -- Fuse Oncology (Fuse), a trailblazing leader in radiation oncology software solutions, is pleased to announce the appointment of Dr. Christel Smith as its new Chief Technology Officer. An accomplished physicist and product innovator with a diverse background spanning physics, medicine, and technology, Dr. Smith joins the Fuse team with a wealth of experience and a passion for revolutionizing cancer care.

Key Points: 
  • BOONE, N.C., Nov. 20, 2023 /PRNewswire/ -- Fuse Oncology (Fuse), a trailblazing leader in radiation oncology software solutions, is pleased to announce the appointment of Dr. Christel Smith as its new Chief Technology Officer.
  • Dr. Smith's exceptional background in developing software that elevates oncology practices and improves cancer treatment across the globe makes her a valuable addition to the Fuse Oncology team.
  • As the new Chief Technology Officer, Dr. Smith will play a crucial role in advancing the company's mission to transform cancer care through technology.
  • "I am honored to join the Fuse Oncology team, where my passion for physics and my commitment to cancer care innovation converge," said Dr. Smith.

Baptist Health Lexington selects RayStation

Retrieved on: 
Thursday, October 26, 2023
Cyberknife, Tomotherapy, RaySearch Laboratories, Patient, Workflow, Pharmaceutical industry, Accuray, Elekta, Varian

STOCKHOLM, Oct. 26, 2023 /PRNewswire/ -- RayStation will be used to treat patients at Baptist Health Lexington as well as Baptist Health Hamburg. It will be used to plan for a wide range of delivery systems, including linear accelerators from Elekta and Varian as well as CyberKnife and Tomotherapy from Accuray. RayStation will also be used for high dose rate brachytherapy planning. The configuration includes advanced features such as fallback planning, multi-criteria optimization, dose tracking and adaptive radiation therapy.

Key Points: 
  • RaySearch Laboratories AB (publ) announces that Baptist Health Lexington, Kentucky, USA, has begun implementation of the treatment planning system RayStation®*.
  • STOCKHOLM, Oct. 26, 2023 /PRNewswire/ -- RayStation will be used to treat patients at Baptist Health Lexington as well as Baptist Health Hamburg.
  • Chris Roty, President, Baptist Health Lexington, says: "We are pleased to be able to implement RayStation in our Baptist System.
  • Right now, RayStation is the only treatment planning system available that can facilitate a unified workflow for such large and diversified centers as Baptist Health Lexington and Baptist Health Hamburg and we are looking forward to a successful collaboration."

iCAD, Inc. Announces Sale of Xoft, its Brachytherapy Business Line, to Elekta

Retrieved on: 
Monday, October 23, 2023
Capital Group Companies, FDA, Inc., NMSC, Cancer, Physician, ICAD, CE, Brachytherapy, Brain, Growth, Disease, Skin, ICAD Inc., Gynecologic cancer disparities in the United States, Patient, Prostate, Medical imaging, Elekta

Elekta is taking over the business effective immediately and will make final payment no later than November 6, 2023.

Key Points: 
  • Elekta is taking over the business effective immediately and will make final payment no later than November 6, 2023.
  • By acquiring the Xoft® Axxent® Electronic Brachytherapy (eBx®) System®, Elekta will be able to offer electronic brachytherapy technology to provide expanded access to treatment for a range of cancers.
  • Xoft's unique technology provides targeted cancer care expertly tailored to meet patients’ personalized needs.
  • We are pleased that Elekta will be acquiring the Xoft subsidiary including both the technology and team,” said Dana Brown, President & CEO of iCAD.

ZAP Surgical Deals Two More Blows to Elekta in IP Suit, Removing Barriers to Mass Adoption of the ZAP-X Radiosurgery Platform

Retrieved on: 
Thursday, September 28, 2023
Legal, Technology, Surgery, Medical Devices, Health Technology, Professional Services, Biotechnology, Health, Robotics, Patent, Radiation, Failure, United States Patent and Trademark Office, Federal Patent Court (Germany), Federal court, Stanford University, Medicine, Judgement, Appeal, IAEA, Patient, ZAP, Isotope, 3D printing, Elekta, Neurosurgery

In April 2019, Elekta alleged that the ZAP-X infringed upon its patent 7,296,648, which described a theoretical design for a radiosurgery device that was never brought to market.

Key Points: 
  • In April 2019, Elekta alleged that the ZAP-X infringed upon its patent 7,296,648, which described a theoretical design for a radiosurgery device that was never brought to market.
  • Elekta’s lawsuit against ZAP Surgical sought monetary damages with a three-fold enhancement for willful infringement, as well as an injunction prohibiting the importation, manufacture, use and sales of the ZAP-X.
  • The judicial panel meticulously reviewed Elekta's arguments and found them “unpersuasive”, thus settling the matter conclusively in favor of ZAP Surgical.
  • This German decision echoes the sentiments expressed by the U.S. courts, further strengthening ZAP Surgical's position in this protracted legal battle.

American Shared Hospital Services Reports Second Quarter 2023 Financial Results

Retrieved on: 
Monday, August 14, 2023
Proton, Operating cost, Esprit, Partnership, Upgrade, Meridian International Center, Interest, Marketing, Proton therapy, Elekta, AMS, Overalls, GK, Cancer, Chemical engineering, Social media, LINAC, EBITDA, Investment, Radiosurgery, Webcast, HVS Global Hospitality Services, Growth, Orlando Health, Three Months, NYSE, MD Anderson Cancer Center, Pharmaceutical industry, Video game, Cryptocurrency, Clothing, Lithium

SAN FRANCISCO, CA, Aug. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy cancer treatment systems and services, today announced financial results for the second quarter ended June 30, 2023.

Key Points: 
  • Operating loss for the second quarter of 2023 was $325,000 compared to operating income of $793,000 in the second quarter of 2022.
  • Adjusted EBITDA, a non-GAAP financial measure, was $1,938,000 for the second quarter of 2023, compared to $2,129,000 for the second quarter of 2022.
  • Net loss attributable to American Shared Hospital Services in the second quarter of 2023 was $111,000, or $(0.02) per diluted share, compared to net income of $497,000, or $0.08 per diluted share, for the second quarter of 2022, and net income of $188,000, or $0.03 per diluted share, reported in the first quarter of 2023.
  • Adjusted EBITDA, a non-GAAP financial measure, was $1,938,000 for the second quarter of 2023, compared to $2,129,000 for the second quarter of 2022.

Radiation therapy treatment rates show improved efficiency, finds New IMV Market Summary Report

Retrieved on: 
Thursday, June 22, 2023
Brainlab, IMV, Accuray, RaySearch Laboratories, Radiation, Cerner, Hospital, Patient, IBA, Com, Brachytherapy, EBRT, Growth, OEM, Medical imaging, Nursing, Science, Elekta, Varian

But these particular data points in the report -- called the IMV 2022-2023 Radiation Therapy Market Summary – reflect a gain in the efficiency of treating patients with radiation therapy, in part due as well to a 5.4% decrease in the average number of visits per course of treatment, report lead and IMV senior market research program manager Davin Korstjens said.

Key Points: 
  • Reduced Number of Patient Visits Needed per Course of Radiation Therapy Treatment, according to a recent IMV's 2022-2023 Radiation Therapy Market Summary report.
  • But these particular data points in the report -- called the IMV 2022-2023 Radiation Therapy Market Summary – reflect a gain in the efficiency of treating patients with radiation therapy, in part due as well to a 5.4% decrease in the average number of visits per course of treatment, report lead and IMV senior market research program manager Davin Korstjens said.
  • The report also found that, although the external beam radiation therapy installed base in the U.S. decreased by 3.3% in 2022, 50% of radiation therapy sites are considering the purchase of an EBRT system in the next three years, Korstjens said.
  • IMV's 2022-2023 Radiation Therapy Market Summary Report explores market trends in U.S. hospitals and imaging centers, including procedure volume, manufacture-installed base features and share, the use of OEM vs. third-party service providers, purchase plans, brand loyalty, and site operations characteristics.

MasterControl Celebrates EMEA Customers’ Achievements in 2023

Retrieved on: 
Wednesday, June 7, 2023
Marfan syndrome, ISO, Elekta, SALT, MDSAP, European Masters, Transplant, Organization, Klosterfrau Melissengeist, Patient, Digital transformation, International Design Excellence Awards, Conference, Nursing, Pharmaceutical industry

These awards recognise MasterControl customers who have excelled in quality and manufacturing innovation and are leaders in their respected professions.

Key Points: 
  • These awards recognise MasterControl customers who have excelled in quality and manufacturing innovation and are leaders in their respected professions.
  • De Koning has been an influential leader in quality management working closely with IT to make certain they are using MasterControl and other technology to its full potential.
  • By using MasterControl Insights, Klosterfrau is able to easily generate reports across different sites, saving time and increasing visibility across operations.
  • “Each one of these organizations are positively impacting patient lives and MasterControl is honored to be a partner to these amazing companies and individuals.”